PO Box 11183

Ellerslie

Auckland 1542

New Zealand

12 October 2023

Dear Healthcare Professional,

**Supply Update: Respigen® (salbutamol)**

Viatris wishes to inform you of changes to the below product.

Summary of Key Changes:

|  |  |  |
| --- | --- | --- |
| Pharmacode | Product Description | Notification |
| 2272911 | RespigenAerosol inhaler, 100mcg per dose CFC free | Discontinuation due to the unforeseen closure of manufacturing site |

Due to closure of the manufacturing site, no further quantities of the above product will be manufactured. For further details, you can access a copy of the discontinuation notice on the PHARMAC website at the following URL: https://pharmac.govt.nz/ under the 'Medicines Notices' tab, last updated 11 October 2023.

The discontinuation takes effect immediately. However, we are currently working with wholesalers to distribute remaining stock into the market over the next couple of weeks. We apologise for any inconvenience this situation may have caused to you and your patients.

Should you require any further information, please do not hesitate to contact our team at infonz@viatris.co.nz. For medical information and adverse event reporting phone 0800 579 811.

Yours Sincerely,

Dirk Potgieter,

National Sales Manager

Respigen® (salbutamol as sulfate) 100 mcg per actuation inhalation aerosol. Prescription Medicine. Indications: treatment and prevention of bronchospasm providing a short acting bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis & emphysema. Respigen® is a fully funded medicine.  Before prescribing Respigen® read the data sheet (available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz) ) for information on dosage, contraindications, precautions, interactions and adverse effects.  Viatris Limited, Auckland. Copyright© Viatris Inc. All rights reserved.

SAL-2023-0010.  TAPS DA2303MM-1009.

This message and any attachments are for the exclusive use of the intended addressee(s). This message may contain confidential, sensitive, privileged and/or proprietary information, and unauthorized review, use or distribution by persons other than the intended addressee(s) is strictly prohibited and may be unlawful. Unintended transmission does not waive any privilege including attorney-client, attorney work product or claims to confidentiality. If you received this message in error or it was forwarded from recipients who received it in error, please contact me by return message and immediately destroy all electronic, paper and other versions of this message. Viatris Inc. and its affiliates and subsidiaries are fully committed to protecting the information relating to identified or identifiable natural persons (“Personal Data”) that we process. This Viatris Privacy Notice (https://www.viatris.nz/en-nz/privacy-policy) describes our collection, use, disclosure, and retention of Personal Data in relation to our websites, apps, services, and platforms, and your use of them, our marketing and provision of products and services, our interactions with you in-person, by calling us, or by mail, and otherwise during the operation of our business. The Notice also explains the ways in which you may, under applicable laws, be able to control our processing of your Personal Data and exercise other rights. This Notice does not apply to Personal Data of members of our workforce in the context of that relationship. To exercise your rights or make a request concerning the processing of your Personal Data, you may contact us by emailing us at dataprivacy@Viatris.com. Thank you.